The ISN-ACT Global Trials Focus team has collected and published a new list of randomized research from nephrologists around the world for August 2020.
Each trial is reviewed in context and the risk of bias in seven key areas is assessed.
Highlight:
Allopurinol does not slow the progression of chronic kidney disease in patients with type 1 diabetes.
See the latest trials here.
Would you like to support equal access to nephrology research? Become an ISN Member
The 2023 ISN Global Kidney Health Atlas (GKHA) sheds light on... read more
The ISN Sharing Expertise to Support the Set-up of Renal Registries... read more
ISN-ACT Global Trials Focus editorial team member Neeru Agarwal summarizes the... read more
Click on the image to expand This visual abstract was supported by... read more
ISN-ACT Global Trials Focus editorial team member Megan Borkum summarizes the... read more
ISN-ACT Global Trials Focus Subgroup member Anastasiia Zykova summarizes the design... read more
The paper "An Update on the Global Disparities in Kidney Disease... read more
As part of the ISN-WHO 2021-2023 collaboration plan, the ISN is... read more
By Yannick Nlandu (DR Congo), YNC member and ISN-GKHA Named Fellow... read more
Discover the "ISN Global Kidney Trials Insights: A Guide for Everyone,"... read more
